HLA class I histocompatibility antigen, A alpha chain (HLA-A*11:01) (HLA-A*11:01)

Human leukocyte antigen A*11:01 (HLA-A*11:01) is a highly prevalent MHC Class I allele, particularly within East Asian and Oceanian populations [1, 5, 12]. It encodes the alpha chain of the HLA-A*11:01 molecule, which forms a heterodimer with beta-2 microglobulin to present intracellularly derived peptides to CD8+ cytotoxic T cells [4, 20]. This allele is a significant therapeutic target in oncology, specifically for T-cell receptor (TCR) engineered T-cell therapies and cancer vaccines targeting "public" neoantigens such as KRAS G12V, PIK3CA H1047L, and mutated NPM1 [6, 9, 10, 11]. Beyond cancer, HLA-A*11:01 plays a vital role in the immune control of viral infections, including influenza A/B, HIV, and Epstein-Barr virus [1, 3, 8]. However, it is also clinically relevant in pharmacogenomics, as it is associated with an increased risk of severe drug-induced hypersensitivity reactions, such as Stevens-Johnson Syndrome, in response to medications like carbamazepine and isoniazid [2, 14]. Effective use of this target requires precise HLA typing and neoantigen screening to ensure therapeutic efficacy and minimize safety risks such as off-target toxicity or cytokine release syndrome [3, 16].

Other names

HLA-A11HLA-A*1101A11A*1101

Presentation of intracellularly derived peptides to CD8+ cytotoxic T cells for immune recognition and elimination of infected or malignant cells.